Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis

Leukemia. 2008 Jun;22(6):1295-8. doi: 10.1038/sj.leu.2405054. Epub 2007 Dec 6.

Authors

E Atallah, R Nussenzveig, C C Yin, C Bueso-Ramos, C Tam, T Manshouri, S Pierce, H Kantarjian, S Verstovsek

PMID: 18059483
DOI: 10.1038/sj.leu.2405054

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Anemia, Refractory / classification
Anemia, Refractory / enzymology
Anemia, Refractory / genetics*
Anemia, Sideroblastic / classification
Anemia, Sideroblastic / enzymology
Anemia, Sideroblastic / genetics*
Female
Humans
Janus Kinase 2 / genetics*
Male
Middle Aged
Myelodysplastic Syndromes / classification
Myelodysplastic Syndromes / enzymology
Myelodysplastic Syndromes / genetics*
Myeloproliferative Disorders / classification
Myeloproliferative Disorders / enzymology
Myeloproliferative Disorders / genetics*
Point Mutation / genetics*
Prognosis
Survival Rate
Thrombocytosis / classification
Thrombocytosis / enzymology
Thrombocytosis / genetics*
World Health Organization

Substances

JAK2 protein, human
Janus Kinase 2